Lantus

Phase 3Small molecule

Sanofi

Lantus is one of 136 small molecule programs targeting Retinopathy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

135

Competitors

Pipeline

Status by Indication[3][1]

Indication

RetinopathyActive, not recruiting

Type 2 Diabetes MellitusUnknown

Type 2 DiabetesActive, not recruiting

Type 1 DiabetesActive, not recruiting

Type 1 Diabetes MellitusUnknown

RetinopathyPhase 1

Active, not recruiting

Type 2 Diabetes MellitusPreclinical

Unknown

Type 2 DiabetesPhase 3

Active, not recruiting

Type 1 DiabetesPhase 3

Active, not recruiting

Type 1 Diabetes MellitusPreclinical

Unknown

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Lantus

Sanofi

Phase 3

5 2

Aurlumyn

BBTG International Inc.

Preclinical

1 3

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

1 4

Sulfonylureas

Eli Lilly

Preclinical

1 5

Blank Control

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Preclinical

1 6

Henagliflozin

TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Preclinical

1 7

Antiplatelet Drug

FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Preclinical

1 8

Insulins

Eli Lilly

Preclinical

1 9

Dipeptidyl Peptidase-4 Inhibitors

Boehringer Ingelheim

Preclinical

2 10

BQ123

VVanderbilt University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Type 1 Diabetes Mellitus9 trials

A Study to Compare Pharmacokinetics and Pharmacodynamics of RinGlar® to Lantus® in Type 1 Diabetes Mellitus Patients

Completed·GGeropharm·N/A·NCT04101383·42 enrolled

A Study to Compare LY2963016 to Lantus After a Single Dose to Participants With Type 1 Diabetes Mellitus

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT01600950·20 enrolled

Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus® in Type 1 Diabetes Mellitus (T1DM) Patients

Completed·MMylan Inc.·Phase 3·NCT02666430·127 enrolled

Show 6 more trials

Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1)

Completed·MMylan Inc.·Phase 3·NCT02227862·558 enrolled

A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT03338023·272 enrolled

A Study of the Safety and Efficacy of MK-1293 Compared to Lantus™ in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02059161·508 enrolled

A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus

Completed· Sanofi logo

Sanofi·Phase 4·NCT02688933·638 enrolled

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus

Completed· Sanofi logo

Sanofi·Phase 3·NCT01683266·549 enrolled

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus on Basal Plus Mealtime Insulin

Completed· Sanofi logo

Sanofi·Phase 2·NCT01658579·59 enrolled

Type 2 Diabetes Mellitus6 trials

A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT02302716·493 enrolled

Dose Range Finding Study of MK-0941 in Patients With Type 2 Diabetes Mellitus on Insulin (MK-0941-007 AM3 EXT1 AM1)(TERMINATED)

Terminated· Merck & Co. logo

Merck & Co.·Phase 2·NCT00767000·813 enrolled

Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2)

Completed·MMylan Inc.·Phase 3·NCT02227875·560 enrolled

Show 3 more trials

The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02059187·531 enrolled

A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 2 Diabetes Mellitus

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT03338010·536 enrolled

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin

Completed· Sanofi logo

Sanofi·Phase 3·NCT01499082·807 enrolled

Type 2 Diabetes5 trials

A Trial to Compare the Pharmacodynamic and Pharmacokinetic Properties of Biochaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes

Completed·AAdocia·Phase 1·NCT02514850·24 enrolled

A Study in Adults With Type 2 Diabetes

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT01421459·759 enrolled

A Trial to Compare Post Prandial Blood Glucose Control of BioChaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes

Completed·AAdocia·Phase 1·NCT02915250·36 enrolled

Show 2 more trials

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy

Completed· Sanofi logo

Sanofi·Phase 3·NCT01499095·811 enrolled

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Completed· Sanofi logo

Sanofi·Phase 3·NCT01676220·878 enrolled

Treatment2 trials

Glycemic Optimization Treatment Study

Completed· Sanofi logo

Sanofi·Phase 4·NCT00552370·5,062 enrolled

Determine Whether Glycemic Control is Different Between Lantus & a 3rd Oral Agent When Failure With Other Treatment

Completed· Sanofi logo

Sanofi·Phase 3·NCT00046462·240 enrolled

GAN2 trials

Gan & Lee Insulin Glargine Target Type (1) Evaluating Research

Completed·GGan and Lee Pharmaceuticals, USA·Phase 3·NCT03371082·576 enrolled

Gan & Lee Insulin Glargine Target Type (2) Evaluating Research

Completed·GGan and Lee Pharmaceuticals, USA·Phase 3·NCT03371108·567 enrolled

9 more indications

ART2 trials

A Study of LY2963016 in Healthy Participants

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT01634165·24 enrolled

A Study of Insulin Glargine (LY2963016) in Healthy Chinese Participants

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT03555305·58 enrolled

Type 1 Diabetes2 trials

A Study in Adults With Type 1 Diabetes

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT01421147·536 enrolled

Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents

Completed· Sanofi logo

Sanofi·Phase 3·NCT00046501·250 enrolled

Type 1 Diabetic1 trial

Immunogenicity Safety Study of Wockhardt's Recombinant Insulin Analogue in Type 1 Diabetic Patients

Withdrawn·WWockhardt·Phase 3·NCT01352663

Retinopathy1 trial

Comparison of Diabetes Retinopathy Among Type 2 Diabetic Patients Treated With Different Regimens

Unknown status·TThird Affiliated Hospital, Sun Yat-Sen University·Phase 1·NCT02587741·600 enrolled

Tics1 trial

A Study to Compare the Pharmacokinetics and Pharmacodynamics of LY2963016 to Lantus in Healthy Participants

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT01476345·80 enrolled

Single Dose1 trial

A Comparison of LY2963016 to a Basal Insulin After a Single Dose in Healthy Subjects

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT01374178·16 enrolled

Aged1 trial

Comparison of Lantus and Neutral Protamine Hagedorn (NPH) Insulin in the Dawn Phenomenon

Completed·MMassachusetts General Hospital·Phase 3·NCT00694122·27 enrolled

PreDiabetes1 trial

Lantus in Prediabetes

Completed· Sanofi logo

Sanofi·Phase 1·NCT00348972·20 enrolled

Unspecified3 trials

Phenotype Evaluation in Insulin Naive Patients Using Lantus (Insulin Glargine)

Completed· Sanofi logo

Sanofi·Phase 4·NCT00653302·280 enrolled

Perioperative Insulin Glargine Dosing Study

Completed·TTamra Dukatz·Phase 4·NCT00309465·402 enrolled

LANN-study: Lantus, Amaryl, Novorapid, Novomix Study

Completed·RRijnstate Hospital·Phase 3·NCT00151697·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 37 trial records for Lantus. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lantus compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lantus. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Sanofi

Lantus

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Type 1 Diabetes Mellitus9 trials

Type 2 Diabetes Mellitus6 trials

Type 2 Diabetes5 trials

Treatment2 trials

GAN2 trials

ART2 trials

Type 1 Diabetes2 trials

Type 1 Diabetic1 trial

Retinopathy1 trial

Tics1 trial

Single Dose1 trial

Aged1 trial

PreDiabetes1 trial

Unspecified3 trials

References

Drug Info

Quick Facts

Related News